• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    T2 Biosystems Appoints Laura Adams to Its Board of Directors

    10/19/21 4:05:00 PM ET
    $TTOO
    Medical/Dental Instruments
    Health Care
    Get the next $TTOO alert in real time by email

    LEXINGTON, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the appointment of Laura Adams to its Board of Directors, effective immediately.

    "We are excited to have Laura join the T2 Biosystems Board of Directors," said John Sperzel, Chairman and CEO at T2 Biosystems. "Her success as a healthcare delivery innovator has deep roots in understanding the critical threats posed by infections and sepsis. She will be a crucial asset to T2 Biosystems as we continue on our growth trajectory."

    Ms. Adams currently serves as Special Advisor at the National Academy of Medicine (NAM), providing leadership for the NAM Digital Health and Evidence Mobilization portfolios. Her primary expertise is digital health transformation, healthcare innovation, and human-centered care and for the past 20 years has held leadership positions across a wide variety of healthcare focused organizations and as a founding member of multiple healthcare IT companies.

    Of note, from 2001 to 2019, Ms. Adams served as the the founding President and CEO of the Rhode Island Quality Institute (RIQI), an organization enabling the best healthcare for the state by providing and connecting trusted data. As part of her tenure she led the Rhode Island Statewide ICU Collaborative as Principal Investigator driving a 62% decrease in catheter-related central line infections; a 48% drop in ventilator-associated pneumonia; a 37% reduction in sepsis mortality; and an estimated $25M in avoided costs. During her time at RIQI, Health Data Management named her one of their 2018 Most Powerful Women in Health IT in the Thought Leader category and Becker's Hospital Review named her to the 2018 and 2019 lists of Female Health IT Leaders to Know.

    Previously, Ms. Adams also chaired the Institute of Medicine's (IOM) Planning Committee for the "Digital Infrastructure for Population Health and a Learning Healthcare System" initiative. Ms. Adams was Founder, President and CEO of Decision Support Systems, a New York-based company specializing in Internet-based healthcare decision support. Laura Adams has been a long-time faculty member of the Institute for Healthcare Improvement (IHI) in Boston. She serves on the board of Translational Medicine Accelerator (TMA), a Boston-based precision medicine company focusing on patients with recalcitrant and rare diseases; and the Oversight Council for the MA Center for Health Information and Analysis. Ms. Adams earned a Master of Science from the University of Colorado Health Sciences Center, and a B.S. from the University of Northern Colorado, of which she was named Distinguished Alumnus in 2010.

    "I am thrilled to join the T2 Biosystems Board of Directors and to assist this team driving innovation focused on a crucial unmet need in healthcare," said Laura Adams. "Over my career I have addressed the unacceptable risks and costs for patients and the healthcare system caused by reliance on blood culture diagnostics to administer targeted therapy for patients suspected of sepsis. I believe T2's transformative culture-independent diagnostics can improve the standard of care for patients at risk of sepsis."

    About T2 Biosystems

    T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems' products include the T2Dx® Instrument, T2Candida® Panel, the T2Bacteria® Panel, the T2Resistance® Panel, and the T2SARS-CoV-2™ Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including the T2Cauris™ Panel, and T2Lyme™ Panel, as well as additional products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers, and biothreat pathogens.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the ability of T2's transformative culture-independent diagnostics to improve the standard of care for patients at risk of sepsis, as well as statements that include the words "expect," "intend," "plan", "believe", "project", "forecast", "estimate," "may," "should," "anticipate," and similar statements of a future or forward looking nature. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, (i) any inability to (a) realize anticipated benefits from commitments, contracts or products; (b) successfully execute strategic priorities; (c) bring products to market; (d) expand product usage or adoption; (e) obtain customer testimonials; (f) accurately predict growth assumptions; (g) realize anticipated revenues; (h) incur expected levels of operating expenses; or (i) increase the number of high-risk patients at customer facilities; (ii) failure of early data to predict eventual outcomes; (iii) failure to make or obtain anticipated FDA filings or clearances within expected time frames or at all; or (iv) the factors discussed under Item 1A. "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2019, filed with the U.S. Securities and Exchange Commission, or SEC, on March 16, 2020, and other filings the Company makes with the SEC from time to time. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, unless required by law, it disclaims any obligation to do so, even if subsequent events cause its views to change. Thus, no one should assume that the Company's silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this press release.

    Media Contact:

    Meagan Dominick, Vault Communications

    [email protected]

    773-369-4255

    Investor Contact:

    Philip Trip Taylor, Gilmartin Group

    [email protected]

    415-937-5406

     



    Primary Logo

    Get the next $TTOO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TTOO

    DatePrice TargetRatingAnalyst
    2/18/2022$0.70Neutral → Buy
    Alliance Global Partners
    More analyst ratings

    $TTOO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Liebman Seymour

      4 - T2 Biosystems, Inc. (0001492674) (Issuer)

      1/2/25 6:58:44 PM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Chief Commercial Officer Giffin Brett A.

      4 - T2 Biosystems, Inc. (0001492674) (Issuer)

      1/2/25 6:55:13 PM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Adams Laura Lee

      4 - T2 Biosystems, Inc. (0001492674) (Issuer)

      1/2/25 6:46:12 PM ET
      $TTOO
      Medical/Dental Instruments
      Health Care

    $TTOO
    SEC Filings

    See more
    • SEC Form 8-K filed by T2 Biosystems Inc.

      8-K - T2 Biosystems, Inc. (0001492674) (Filer)

      4/4/25 5:47:15 PM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • SEC Form NT 10-K filed by T2 Biosystems Inc.

      NT 10-K - T2 Biosystems, Inc. (0001492674) (Filer)

      4/1/25 9:00:30 AM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • SEC Form 8-K filed by T2 Biosystems Inc.

      8-K - T2 Biosystems, Inc. (0001492674) (Filer)

      2/20/25 9:00:24 AM ET
      $TTOO
      Medical/Dental Instruments
      Health Care

    $TTOO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by T2 Biosystems Inc.

      SC 13G - T2 Biosystems, Inc. (0001492674) (Subject)

      11/14/24 3:38:45 PM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by T2 Biosystems Inc.

      SC 13G - T2 Biosystems, Inc. (0001492674) (Subject)

      11/6/24 9:02:19 PM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by T2 Biosystems Inc.

      SC 13G - T2 Biosystems, Inc. (0001492674) (Subject)

      11/6/24 9:01:48 PM ET
      $TTOO
      Medical/Dental Instruments
      Health Care

    $TTOO
    Financials

    Live finance-specific insights

    See more
    • T2 Biosystems Announces Third Quarter 2024 Financial Results

      LEXINGTON, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the "Company"), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced financial and operational results for the third quarter ended September 30, 2024. Recent Financial and Commercial Highlights Achieved third quarter total revenue of $2.0 million, representing an increase of 34% compared to the prior year period.Achieved sepsis test panel revenue of $1.4 million, representing an increase of 34% compared to the prior year period, driven by increased U.S. T2Bacteria® Panel revenue.Executed contracts for 11 T2Dx® Instruments during the third quar

      11/14/24 4:05:00 PM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • T2 Biosystems to Report Third Quarter 2024 Financial Results and Business Updates on November 14, 2024

      LEXINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the third quarter 2024 and business updates after market close on Thursday, November 14, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.t2biosystems.com, on the Investors page in the Events & Presentations section. To listen to the conference call, please dial 877-545-0320

      11/5/24 8:00:00 AM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • T2 Biosystems to Host Business Update Call on October 10, 2024

      LEXINGTON, Mass., Oct. 08, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will host a business update call to provide additional details on recent developments after market close at 4:30pm ET on Thursday October 10, 2024. On the call management also plans to address select questions from shareholders that can be submitted in advance to the investor relations team at [email protected]. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.t2biosystems.com, on the Investors page in the

      10/8/24 4:05:00 PM ET
      $TTOO
      Medical/Dental Instruments
      Health Care

    $TTOO
    Leadership Updates

    Live Leadership Updates

    See more

    $TTOO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $TTOO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors

      Avacta Group plc Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors London, England; July 8, 2024; Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted cancer treatments and powerful diagnostics, today announced the appointment of Darlene Deptula-Hicks, MBA as a Non-Executive Director of the Company's Board of Directors, effective 26 June 2024. Ms. Deptula-Hicks is a highly accomplished financial executive with decades of experience working with and advising private and public life sciences companies. Shaun Chilton, Chairman of the Board of Avacta, commented: "Avacta is at a pivotal time in its e

      7/8/24 8:15:00 AM ET
      $PIRS
      $TTOO
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • T2 Biosystems Hires Industry Veteran Brett Giffin as Chief Commercial Officer

      LEXINGTON, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the appointment of Brett Giffin as its Chief Commercial Officer, effective November 8, 2021. As Chief Commercial Officer, Mr. Giffin will join the Company's executive leadership team and lead our commercial growth initiatives with direct responsibility for global sales, marketing, service, and customer support functions. Mr. Giffin replaces Anthony Pare, who recently accepted a role as CEO at BioPorto A/S. "We are thrilled to have Brett join T2 Biosystems as Chief Commercial Officer," said John Sperzel, Chairman and CEO at T2

      11/4/21 4:04:00 PM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • T2 Biosystems Appoints Laura Adams to Its Board of Directors

      LEXINGTON, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the appointment of Laura Adams to its Board of Directors, effective immediately. "We are excited to have Laura join the T2 Biosystems Board of Directors," said John Sperzel, Chairman and CEO at T2 Biosystems. "Her success as a healthcare delivery innovator has deep roots in understanding the critical threats posed by infections and sepsis. She will be a crucial asset to T2 Biosystems as we continue on our growth trajectory." Ms. Adams currently serves as Special Advisor at the National Academy of Medicine (NAM), providing lead

      10/19/21 4:05:00 PM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • T2 Biosystems upgraded by Alliance Global Partners with a new price target

      Alliance Global Partners upgraded T2 Biosystems from Neutral to Buy and set a new price target of $0.70

      2/18/22 10:16:52 AM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • Alliance Global Partners resumed coverage on T2 Biosystems with a new price target

      Alliance Global Partners resumed coverage of T2 Biosystems with a rating of Neutral and set a new price target of $1.65 from $2.40 previously

      3/5/21 7:31:44 AM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • T2 Biosystems downgraded by Alliance Global Partners with a new price target

      Alliance Global Partners downgraded T2 Biosystems from Buy to Neutral and set a new price target of $2.40 from $2.60 previously

      1/27/21 8:12:03 AM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

      LEXINGTON, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the "Company"), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced preliminary unaudited financial and operational results for the fourth quarter and full year ended December 31, 2024. Full Year 2024 and Recent Commercial Highlights (unaudited) Achieved record product revenues of $2.3 million for the fourth quarter of 2024 and $8.3 million for the full-year 2024, representing increases of 37% and 23% respectively, compared to the prior year period, driven by record sepsis test sales.Executed contracts for 27 T2Dx® Instruments in 2024, including

      1/7/25 9:00:00 AM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • T2 Biosystems Announces Sale of Four T2Dx Instruments to Existing European Distributor

      LEXINGTON, Mass., Dec. 18, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the sale of four T2Dx® Instruments to its European (EU) distributor that represents multiple EU counties, demonstrating commercial expansion and increased international market penetration. The multiple instrument sale demonstrates commercial expansion to enable increased utilization of the T2Bacteria® Panel, the T2Candida® Panel, and the T2Resistance® Panel. The target hospitals for the new instruments include: Selling a second T2Dx Instrument to a major reference hospital to expand "same st

      12/18/24 9:00:00 AM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • T2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped Globally

      LEXINGTON, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has surpassed the shipment of 250,000 sepsis tests, marking a significant milestone that underscores the growing customer adoption of the Company's direct-from-whole-blood technology. A meta-analysis of 14 controlled studies, published in a peer-reviewed medical journal, compared T2 Biosystems' sepsis tests to blood culture-based diagnostics, and showed that T2 Biosystems' products provided: faster time to detection (e.g., species identification 77 hours faster), faster targeted therapy (

      12/17/24 9:00:00 AM ET
      $TTOO
      Medical/Dental Instruments
      Health Care